We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our
Privacy Policy
Profacgen offers Functional Similarity Assessment & Bioassays service, providing comprehensive biological activity comparison demonstrating that biosimilar candidates and post-change products maintain equivalent therapeutic function to their reference or pre-change counterparts. Our programs integrate mechanism-of-action (MOA)-driven assay selection, orthogonal functional evaluation, and rigorous statistical potency comparison to generate regulatory-defensible functional similarity conclusions.
Structural similarity alone is insufficient for biosimilar approval. A protein may possess identical primary sequence and comparable physicochemical properties yet exhibit altered biological activity due to subtle differences in conformation, glycosylation, or aggregation state that escape structural detection. Functional assessment confirms that these structural features translate into equivalent therapeutic effect, providing the biological relevance bridge between analytical data and clinical outcomes. Regulatory agencies consistently emphasize that functional equivalence is a non-negotiable component of the totality of evidence.
Introduction to Functional Similarity
The biosimilar paradigm rests on the principle that analytical similarity reduces residual uncertainty, enabling streamlined clinical programs. However, this uncertainty reduction is credible only when the analytical package includes comprehensive functional assessment. Structural methods—mass spectrometry, chromatography, electrophoresis—detect molecular features but cannot predict how these features influence biological activity. Functional assays provide the empirical validation that structural similarity translates into therapeutic equivalence.
Mechanism-of-action (MOA) drives functional assay selection. A receptor antagonist requires binding inhibition assays; a cytotoxic antibody requires ADCC and CDC evaluation; a growth factor requires proliferation stimulation assessment. Assay selection must reflect the specific therapeutic mechanism, with orthogonal methods providing independent confirmation of functional equivalence. This MOA-driven approach ensures that functional assessment addresses the biological activities most relevant to clinical performance.
Key principles of functional similarity assessment include:
Structural similarity is necessary but not sufficient: Comprehensive physicochemical data must be complemented by biological activity demonstration
MOA-driven assay selection: Functional evaluation must reflect the specific therapeutic mechanism, not generic activity metrics
Orthogonal functional evaluation: Multiple independent biological assays increase confidence that functional equivalence is genuine rather than assay-specific
Totality of evidence integration: Functional data combined with structural, purity, and stability data form the integrated similarity conclusion
Functional Similarity Strategy
Profacgen employs a tiered, risk-based functional similarity strategy aligned with FDA, EMA, and WHO biosimilar guidelines:
Tier 1 functional CQAs: Biological activities most critical to therapeutic mechanism (e.g., binding affinity, potency, effector function) requiring equivalence testing with 90% confidence intervals
Tier 2 functional attributes: Activities of moderate relevance (e.g., secondary signaling, off-target binding) evaluated with quality range comparison
Orthogonal functional evaluation: Independent assay platforms assessing the same functional attribute through different biological principles
Risk-based assay selection: Concentration of analytical effort on functions most likely affected by observed or potential structural differences
Comparative potency assessment: Relative potency determination with reference standard calibration and statistical equivalence evaluation
What Profacgen Offer>
Binding & Receptor Interaction Assays
Binding assays evaluate the primary molecular interaction between therapeutic protein and target receptor, providing quantitative measures of affinity and kinetics:
Surface plasmon resonance (SPR): Real-time kinetic analysis of association and dissociation rates, enabling determination of equilibrium dissociation constant (KD) and comparison of binding kinetics between biosimilar and reference
Bio-layer interferometry (BLI): Label-free binding analysis with high throughput capability, suitable for multi-lot comparison and temperature-dependent binding assessment
Receptor occupancy assessment: Cell-based or bead-based evaluation of competitive binding and saturation characteristics, confirming equivalent target engagement
Affinity comparison: Equilibrium binding constants determined by Scatchard analysis or saturation binding, with statistical evaluation of equivalence margins
Cell-Based Functional Bioassays
Cell-based assays demonstrate biological activity in physiologically relevant systems, confirming that binding translates into functional cellular response:
Proliferation assays: Cell growth stimulation or inhibition measured by metabolic activity, DNA synthesis, or direct cell counting, reflecting growth factor or cytostatic mechanisms
Apoptosis assays: Programmed cell death induction evaluated by caspase activation, DNA fragmentation, or membrane integrity changes, confirming cytotoxic mechanisms
Reporter gene assays: Luciferase or GFP-based readouts of signaling pathway activation, providing sensitive, quantitative measures of receptor-mediated transcriptional response
Signaling pathway activation: Phosphorylation-specific Western blot, flow cytometry, or multiplex bead array assessment of intracellular signaling cascades
Fc-Mediated Functional Assays
For antibody therapeutics, Fc-mediated effector functions are critical quality attributes requiring comprehensive comparison:
Antibody-dependent cellular cytotoxicity (ADCC): NK cell-mediated target cell killing evaluated by chromium release, LDH release, or flow cytometry with effector-to-target ratio optimization
Complement-dependent cytotoxicity (CDC): Complement cascade activation and target cell lysis measured by viability assays with serum complement source standardization
Antibody-dependent cellular phagocytosis (ADCP): Macrophage-mediated target engulfment assessed by flow cytometry or microscopy with phagocytic index quantification
Fcγ receptor binding: Affinity and kinetics evaluation for FcγRI, FcγRIIa, FcγRIIIa variants by SPR or ELISA, confirming effector function potential
Relative Potency Assessment
Potency is the quantitative measure of biological activity and the most critical functional CQA for biosimilar assessment. Profacgen employs rigorous relative potency determination with statistical equivalence evaluation:
Dose-response comparison: Parallel-line or four-parameter logistic curve fitting with parallelism testing to confirm similar dose-response relationships
Potency equivalence: Relative potency expressed as ratio of biosimilar to reference with 95% confidence interval, evaluated against predefined equivalence margins
Bioactivity consistency: Evaluation of potency across multiple lots to confirm batch-to-batch consistency and absence of process drift
Reference standard calibration: Traceable potency assignment with pharmacopeial or qualified reference standards ensuring calibration consistency across testing campaigns
Statistical model validation: Confirmation of model fit, residual analysis, and variance homogeneity to ensure valid potency estimation
Biosimilar-Specific Assay Development
Biosimilar functional assessment requires assay development considerations distinct from innovator product characterization:
Reference product bridging: Assay calibration and validation using reference product as the primary standard, with bridging studies to qualified working standards
Assay sensitivity optimization: Method refinement to detect differences of regulatory and clinical relevance, with sensitivity demonstrated through spiking and forced degradation studies
Matrix effects evaluation: Assessment of formulation components, excipients, and container-closure leachables on assay performance
Assay qualification: Formal demonstration of precision, accuracy, and robustness for biosimilar-specific applications, with documentation supporting regulatory submission
Data Interpretation & Similarity Assessment
Functional data achieve regulatory value only when interpreted within a structured similarity framework with predefined acceptance criteria:
Acceptance criteria establishment: Predefined potency equivalence margins, binding affinity ranges, and effector function thresholds based on reference product variability and clinical relevance
Statistical comparison: Equivalence testing (TOST) for Tier 1 functional CQAs, quality range analysis for Tier 2, and descriptive evaluation for Tier 3
Variability assessment: Comparison of inter-assay and inter-lot variability between biosimilar and reference to confirm equivalent process control
Interpretation of observed differences: Structured evaluation of whether statistically significant differences are clinically meaningful, considering magnitude, direction, and mechanism-of-action relevance
Applications
Functional similarity assessment supports diverse regulatory and development scenarios:
MOA-Driven Assay Selection: Functional assays are selected based on specific therapeutic mechanism rather than generic activity panels, ensuring that assessment addresses the biological functions most relevant to clinical efficacy and regulatory review.
Orthogonal Functional Confirmation: Multiple independent assay platforms assess the same functional attribute through different biological principles, preventing assay-specific artifacts and increasing confidence in equivalence conclusions.
Rigorous Potency Determination: Relative potency assessment with validated statistical models, parallelism confirmation, and reference standard traceability provides quantitative equivalence evidence that withstands regulatory scrutiny.
Biosimilar-Specific Assay Development: Assays are developed and qualified specifically for biosimilar comparison, with sensitivity optimized to detect clinically relevant differences and reference product bridging ensuring calibration consistency.
Integrated Data Interpretation: Functional results are interpreted within structured similarity frameworks with predefined acceptance criteria, preventing subjective conclusions and supporting defensible regulatory submissions.
Fc Effector Function Expertise: Specialized capabilities in ADCC, CDC, ADCP, and Fcγ receptor binding assessment for antibody therapeutics, with effector cell sourcing, complement standardization, and assay validation supporting robust comparison.
Representative Case Studies
Case 1: Functional Similarity Strategy for Biosimilar Monoclonal Antibody
Background:
A biosimilar developer required comprehensive functional similarity assessment for a monoclonal antibody targeting an oncology indication. The reference product's therapeutic mechanism relied on both direct growth inhibition and Fc-mediated cytotoxicity, requiring multi-dimensional functional comparison.
Our Solution:
Profacgen designed a tiered functional strategy: Tier 1 included binding affinity by SPR (KD comparison), cell-based proliferation inhibition (IC50 equivalence), and ADCC potency (relative potency with 90% CI). Tier 2 included CDC activity, FcγRIIIa binding, and apoptosis induction. Orthogonal confirmation employed BLI as an independent binding platform and an alternative ADCC effector cell source. Potency was determined by parallel-line analysis with reference product calibration.
Final Results:
All Tier 1 functional CQAs met equivalence criteria: binding KD ratio 1.04 (90% CI 0.92–1.18), proliferation IC50 ratio 0.98 (90% CI 0.87–1.11), ADCC relative potency 1.02 (90% CI 0.91–1.15). Tier 2 attributes showed equivalent or slightly improved CDC activity. The functional package supported FDA scientific advice with positive feedback, contributing to a reduced clinical program and successful 351(k) submission.
Case 2: Potency Equivalence Investigation After Manufacturing Change
Background:
A post-change lot of a therapeutic protein showed a 12% decrease in cell-based potency compared to pre-change baseline, exceeding the predefined quality range. The difference threatened to delay a critical manufacturing technology transfer and required rapid functional investigation.
Our Solution:
Profacgen executed structured difference investigation: (1) analytical artifact exclusion through re-testing with alternative potency assays and reference standard verification; (2) root cause analysis linking the decrease to bioreactor pH shift affecting glycosylation and subsequent receptor binding; (3) orthogonal functional confirmation showing equivalent in vivo pharmacokinetics and pharmacodynamics in a relevant animal model; (4) clinical relevance assessment demonstrating that the 12% difference was within the reference product's demonstrated therapeutic window.
Final Results:
The investigation established that the potency decrease was real but clinically irrelevant, with orthogonal in vivo data providing decisive confirmation. The comparability package included comprehensive justification for accepting the difference, supported by mechanism-of-action analysis and clinical relevance assessment. The technology transfer proceeded on schedule with regulatory acceptance of the comparability conclusion.
Q: Why are functional assays required for biosimilar assessment?
A: Functional assays are required because structural similarity alone cannot confirm therapeutic equivalence. Subtle differences in conformation, glycosylation, or aggregation that escape structural detection may alter biological activity. Functional assessment empirically validates that the biosimilar produces equivalent cellular and physiological responses, providing the biological relevance bridge between analytical data and clinical outcomes required by FDA, EMA, and WHO guidelines.
Q: How is potency compared between biosimilar and reference product?
A: Potency is compared through relative potency determination using validated bioassays. Both products are tested in the same assay run with identical conditions, and dose-response curves are fitted with parallel-line or four-parameter logistic models. Relative potency is expressed as the ratio of biosimilar to reference with a confidence interval, evaluated against predefined equivalence margins. Reference product serves as the concurrent standard ensuring calibration consistency.
Q: What functional assays are commonly used for biosimilar assessment?
A: Common assays include: binding assays (SPR, BLI, ELISA) for affinity and kinetics; cell-based assays (proliferation, apoptosis, reporter gene) for mechanism-of-action confirmation; Fc-mediated assays (ADCC, CDC, ADCP, FcγR binding) for antibody effector function; and in vivo pharmacokinetic/pharmacodynamic studies where required. Assay selection is MOA-driven, focusing on functions most relevant to therapeutic efficacy.
Q: How are functional assay differences interpreted?
A: Observed differences are interpreted through structured evaluation: (1) verify the difference is product-related rather than analytical artifact; (2) assess magnitude against predefined acceptance criteria; (3) evaluate clinical relevance based on mechanism of action and therapeutic window; (4) consider orthogonal confirmation from independent assays; (5) determine whether additional studies or process modification are required. Differences within equivalence margins with no clinical relevance are accepted as not meaningful.
Q: What is the role of orthogonal functional evaluation?
A: Orthogonal evaluation uses independent assay platforms to assess the same functional attribute through different biological principles. For example, binding may be evaluated by both SPR (kinetic) and ELISA (equilibrium). Orthogonal confirmation increases confidence that observed equivalence is genuine rather than an artifact of a specific assay format, reducing residual uncertainty and strengthening regulatory submissions.
Q: How are Fc effector functions assessed for antibody biosimilars?
A: Fc effector functions are assessed through ADCC (NK cell-mediated killing), CDC (complement-mediated lysis), ADCP (macrophage phagocytosis), and Fcγ receptor binding assays. Each assay requires careful standardization of effector cells, complement source, and target cells. Relative potency is determined against reference product with equivalence evaluation, and glycosylation differences are correlated with effector function changes to assess clinical relevance.
Q: Can functional similarity reduce clinical study requirements?
A: Yes. Comprehensive functional similarity demonstrating equivalent biological activity supports reduced clinical programs, particularly when combined with extensive structural and physicochemical similarity. FDA and EMA have approved biosimilars based primarily on analytical and pharmacokinetic data when functional equivalence is thoroughly demonstrated. The extent of reduction depends on product class, mechanism complexity, and regulatory precedent.
References:
FDA Guidance for Industry. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. U.S. Food and Drug Administration; 2015.
EMA. Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-Clinical and Clinical Issues. European Medicines Agency; 2014.
WHO. Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs). World Health Organization; 2009.
United States Pharmacopeia. USP General Chapter <1032>: Design and Development of Biological Assays. United States Pharmacopeial Convention; current edition.
Cao D, Deng C, Wang G, et al. Physicochemical and functional similarity assessment between proposed bevacizumab biosimilar bat1706 and reference bevacizumab. Drugs R D. 2023;23(3):267-288. doi:10.1007/s40268-023-00432-8
Online Inquiry
Fill out this form and one of our experts will respond to you within one business day.
